Dr. Lee received his Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology.  He has a broad range of industrial experiences in bioprocess development, commercial product launches and biologics manufacturing.  Previously he held various engineering, management and executive positions at Hoffman-La Roche, Inc., Merck & Co., and Bristol Myers Squibb Company.  Most recently before joining A-Bio, Dr. Lee held the position of Vice President and General Manager of the BMS Syracuse, New York, Biologics Manufacturing and Process Development complex overseeing over 800 employees and a wide range of biological drugs and development candidates including antibody therapeutics.

Dr. Loh is the Director of GMP Operations. He holds a first class honors B.Eng. (Hons) in Biochemical Engineering from the University College London, United Kingdom and received his Ph.D. in Chemical Engineering from the National University of Singapore. He has held various R&D, engineering and project management positions at Singapore Biotech Pte Ltd, Bioprocessing Technology Centre (BTC) and DSM Biologics.  Prior to joining A-Bio, he was the Senior Manager of process engineering and validation at the Biopharmaceutical Manufacturing Technology Centre (BMTC).

Dr. Gordon has responsibility for the Quality and Regulatory functions at A-Bio. He received his Ph.D. in physiology and biophysics from the University of Illinois and did post-doctoral training in protein purification and characterization at the University of Texas M.D. Anderson Cancer Center.  Since then he held various positions in downstream purification and analytical development, quality control, quality assurance and regulatory affairs at Tanox, Inc. USA.  He was Senior Director of Quality of Tanox, Inc., before joining A-Bio in January of 2008.

Dr. Wong is the Head of Upstream Process Development and is in charge of cell culture activities focusing on cell line development; serum-free media development; fed-batch and perfusion culture optimization; bioreactor scale up and disposable reactor scale-up for vaccine and antibody process development.  She received her B. Eng and Ph.D. degree in Chemical Engineering from the University of Queensland, Australia.  She has over 15 years of experience in mammalian and insect cell culture.  Prior to joining A-Bio, she was Senior Research Scientist at the Bioprocess Technology Institute (BTI) where she led the Animal Cell Technology Group and co-developed BTI's platform protein-free medium and fed-batch process for animal cell culture.  She was also involved in a multitude of research projects in metabolic engineering, utilizing genomic and proteomic tools for the analysis of CHO bioprocesses.

Ms Ng is responsible for the finance and treasury functions as the Financial Controller of A-Bio.  She holds a Bachelor degree in Accounting and Finance from the University of Strathclyde, United Kingdom, and is a Fellow of the Association of Chartered Certified Accountants (FCCA) and a member of the Institute of Certified Public Accountants of Singapore (CPA).  Ms Ng has spent her career to date working for multinational companies in the biotech R&D, IT, telecommunications, freight forwarding and oil and gas sectors in the Asia Pacific region.  She has more than 10 years of experience in financial management, accounting, strategic planning and budgeting, audit, taxation, company secretarial as well as human resources.